<DOC>
	<DOCNO>NCT02722408</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability multiple dos Gemcabene patient HoFH stable , lipid-lowering therapy .</brief_summary>
	<brief_title>Efficacy Safety Gemcabene Patients With Homozygous Familial Hypercholesterolemia Stable , Lipid-Lowering Therapy ( COBALT-1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>Provision write sign informed consent ( patient legal guardian ) prior studyspecific procedure ; Male female ≥17 year age time consent ; Diagnosis HoFH genetic confirmation ( include compound heterozygosity ) clinical diagnosis base either ( 1 ) history untreated LDLC concentration &gt; 500 mg/dL ( 12.92 mmol/L ) together either appearance xanthoma 10 year age , evidence heterozygous familial hypercholesterolemia parent , history unavailable , ( 2 ) LDLC &gt; 300 mg/dL ( 7.76 mmol/L ) maximally tolerate lipidlowering drug therapy ; Currently stable , lowfat , lowcholesterol diet combination preexisting , regulatoryapproved , exclude lipidlowering therapy ( i.e. , statin , monoclonal antibody PCSK9 , cholesterol absorption inhibitor , bile acid sequestrants , nicotinic acid , combination thereof ) stable dose least 4 week prior Screening Visit ; Fasting LDLC value &gt; 130 mg/dL ( 3.36 mmol/L ) Screening Visit ; Physical examination , include vital sign , within normal limit clinically acceptable Investigator ; Weight ≥50 kg ; Female patient must pregnant lactating . Women childbearing potential must negative serum pregnancy test Screening Visit negative urine dipstick Day 1 prior dose order qualify study . Women surgically sterile clinically confirm postmenopausal ( i.e. , document amenorrhea ≥1 year absence biological physiological cause ) consider childbearing potential ; Women childbearing potential must agree use acceptable method contraception throughout duration study 30 day last dose study drug . For study , doublebarrier contraception require . Other form primary hyperlipoproteinemia secondary cause hypercholesterolemia ( e.g. , nephrotic syndrome hypothyroidism ) ; Abnormal liver function test Screening Visit ( aspartate aminotransferase alanine aminotransferase &gt; 2 × upper limit normal [ ULN ] ; total bilirubin &gt; 1.5 × ULN ; alkaline phosphatase &gt; 2 × ULN base appropriate age gender normal value ) . Patients bilirubin &gt; 1.5 × ULN history Gilbert 's syndrome may include ; reflexive direct bilirubin test use confirm Gilbert 's syndrome ; Moderate ( Grade B ) severe ( Grade C ) chronic hepatic impairment accord Child Pugh classification ; Active liver disease ( e.g. , cirrhosis , alcoholic liver disease , hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] , autoimmune hepatitis , liver failure , liver cancer ) , history liver transplant , know diagnosis human immunodeficiency virus ( HIV ) ; Triglycerides value &gt; 400 mg/dL ( 4.52 mmol/L ) Screening Visit ; Moderate severe renal insufficiency define estimate GFR &lt; 30 mL/min/1.73m2 ( calculate use The Chronic Kidney Disease Epidemiology Collaboration equation ) Screening Visit ; Abnormal urinalysis ( proteinuria great trace male nonmenstruating female great trace hematuria ) , confirm reflexive urine protein : creatinine ratio test ; Uncontrolled thyroid disease : hyperthyroidism hypothyroidism define thyroid stimulate hormone ( TSH ) low limit normal &gt; 1.5 × ULN , respectively , Screening Visit . If control , treatment stable least 3 month prior Screening Visit ; Type 1 diabetes mellitus uncontrolled type 2 diabetes mellitus ( hemoglobin A1c [ HbA1c ] value &gt; 8 % ) , diabetic patient take insulin and/or thiazolidinediones ; New York Heart Association Class III IV heart failure ; Myocardial infarction , severe unstable angina pectoris , coronary angioplasty , coronary artery bypass graft , major cardiovascular event result hospitalization within 3 month Screening Visit . Patients adequately treat stable angina , per Investigator assessment , may include ; Uncontrolled cardiac arrhythmia prolong QT Screening Visit Day 1 prior dose ECG ( QTcF &gt; 450 msec men &gt; 470 msec woman ) know family history prolong QT unexplained sudden cardiac death ; Uncontrolled hypertension , define sit systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg , confirm repeat measurement ; Currently receive cancer treatment , Investigator 's opinion , risk relapse recent cancer ; Use fibrate lipidlowering agent 6 week prior Screening Visit ; Hypersensitivity history significant adverse reaction fibrate lipid lowering agent ; Use apheresis ( LDL plasma ) 8 week prior Screening Visit ; Use lomitapide 2 month prior Screening Visit ; Use mipomersen 5 month prior Screening Visit ; Use exclude medication supplement ( e.g. , potent cytochrome P450 [ CYP ] 3A4 inhibitor ) ; History drug alcohol abuse within past year inability comply protocol requirement , include subject restriction ; Previously treat gemcabene ; Participation another clinical study investigational agent device concurrently within 1 month prior Screening Visit , use investigational agent within 1 month 5 halflives ( know ) , whichever longer , prior Screening Visit ; Any finding , opinion Investigator , would compromise patient 's safety participation study .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>Lipid Regulator</keyword>
</DOC>